Skip to content
Screener

Harmony Biosciences Holdings, Inc. HRMY Total Liabilities

Total Liabilities at other companies

Alkermes logo
AlkermesALKS
$2.58B+311%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$659.02M+21.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$48.4M-14.8%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$436.29M+8.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$14.57M-89.5%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$49.06M+0.9%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$2.26B+13.1%
Enterprise value$1.83B+12.9%
P/E15.5×+4.5×
P/S2.5×-0.1×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:16 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056720
Line itemMarch 31, 2026December 31, 2025
Long-term debt, net138,814143,663
Other noncurrent liabilities5,3215,618
Total noncurrent liabilities144,135149,281
TOTAL LIABILITIES361,475401,413
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS’ EQUITY:
Common stock—$0.00001 par value; 500,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 57,867,389 and 57,726,170 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively11
Additional paid in capital717,370708,968

Item 1. Financial Statements

FAQ

What is Harmony Biosciences Holdings, Inc.'s total liabilities?
Harmony Biosciences Holdings, Inc. (HRMY) reported total liabilities of $361.48M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s total liabilities changed year-over-year?
Harmony Biosciences Holdings, Inc.'s total liabilities increased by 7.9% year-over-year, from $335.01M to $361.48M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s total liabilities has grown at a 4.0% compound annual growth rate (CAGR), from $329.89M to $401.41M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Harmony Biosciences Holdings, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude